Skip to content

Nasal and Gut Microbiota Combined Clinical Events Predicts the Prognosis of Septic Patients

Nasal and Gut Microbiota Combined Clinical Events Predicts the Prognosis of Patients With Sepsis: a Prospective, Multicentered, Diagnostic Trial

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05143736
Enrollment
300
Registered
2021-12-03
Start date
2022-01-10
Completion date
2025-01-31
Last updated
2024-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis, Septic Shock

Keywords

Sepsis, Septic Shock, nasal microbiota, gut microbiota

Brief summary

In this prospective, multicentered , diagnostic trial, nasal and fecal specimens will collected from patients with sepsis in two critical care units(ICU) at the enrollment day ,the third, seventh, and fourteen days after enrollment or until ICU discharge (whatever come first). Total DNA from the nasal and fecal specimens will be extracted, amplified, and sequenced to determined the characteristics of gut microbiota and nasal microbiota. Finally, the characteristics of gut microbiota and nasal microbiota combined clinical information will be used to construct a prediction model to predict the prognosis of sepsis.

Detailed description

Background: Sepsis should be defined as life-threatening organ dysfunction caused by a dysregulated host response to infection, with high morbidity and mortality, and its total mortality is 10% to 52%. In sepsis, it is not clear sufficiently about the relationship between intestinal and nasal microbiota character and the development of the sepsis.The study aim to construct a prediction model to predict the prognosis and development of sepsis. Purpose: 1. To construct a prediction model using nasal and gut microbiota combined with clinical events to predict the prognosis of patients with sepsis and development of sepsis. 2. Analyze the characteristics of nasal and gut microbiota in patients with sepsis using microbiology. Methods: nasal and fecal specimens will collected from patients with sepsis in two critical care units(ICU) at the enrollment day ,the third, seventh, and fourteen days after enrollment or until ICU discharge (whatever come first). Total DNA from the nasal and fecal specimens will be extracted, amplified, and sequenced to determined the characteristics of gut microbiota and nasal microbiota. Meanwhile, some related clinical information also will be collected,including demographic characteristics, comorbidities, infection site, results of the microbiology experiments, vital signs, invasive tubing indwelling at enrollment,combined medication,the requirement of organ function support, laboratory indexing, sequential organ failure assessment score and Acute Physiology and Chronic Health Evaluation score. Finally, the characteristics of gut microbiota and nasal microbiota combined the clinical information will be used to construct a prediction model to predict the prognosis of sepsis. The primary outcome is the 28-day all-cause mortality. The secondary outcomes are the incidence of septic shock, the incidence of persistent inflammation- immunosuppression catabolism syndrome and the 90-day all-cause mortality.

Interventions

DIAGNOSTIC_TESTgut and nasal microbiota detection

The nasal and fecal specimens will be collected by swabs from subjects with sepsis. After that, total DNA of nasal and gut microbiota will be extracted , amplified, and sequenced to determine the gut and nasal microbiota.

Sponsors

Zhujiang Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years

Inclusion criteria

1. Meet the 2016 International Sepsis Guidelines diagnostic criteria (sepsis 3.0). 2. Serum procalcitonin≥ 2 ng/mL at enrollment.

Exclusion criteria

Patients will be excluded if participants meet any of the following criteria: 1. age\<18 years old or \> 80 years 2. pregnancy or lactation 3. solid organ or bone marrow transplant 4. advanced pulmonary fibrosis 5. HIV-positive 6. neutropenia; 7. hematological/lymphatic tumors have no remission; 8. limited care (lack of commitment to full and aggressive support); 9. long-term use of immunosuppressive drugs or immunodeficiency; 10. advanced tumors; 11. combined with noninfectious factors leading to death (uncontrolled large bleeding, cerebral hernia, etc.); 12. Combined with autoimmune diseases 13. Paraquat poisoning 14. Combined with Nasopharyngeal carcinoma 15. Combined with chronic nasosinusitis 16. Combined with severe nasal injuries

Design outcomes

Primary

MeasureTime frameDescription
All-cause death at 28 daysThe outcome will be assessed on the 28th day from enrollmentAll-cause mortality from the enrollment to the 28th day

Secondary

MeasureTime frameDescription
Incidence of septic shockThe outcome will be assessed diurnally until ICU discharge,the longest evaluation duration is no more than 28 daysIncidence of septic shock during the ICU stay.
Incidence of persistent inflammation-immunosuppression catabolism syndrome (PICS)The outcome will be assessed diurnally until ICU discharge,the longest evaluation duration is no more than 28 daysThe incidence of PICS during the ICU stay. Patients who meet all the following diagnostic criteria will be diagnosed PICS: 1) the duration of ICU stay more than 14 days, 2) the level of serum C reactive protein \> 50ug/dL, 3) Lymphocyte counts\<0.80\*10\^9/L,4) serum albumin\<3g/dL, 5) serum prealbumin\<10mg/dL, 6) The creatinine height index\<80%. 7)weight loss more than 18% or BMI\<18

Countries

China

Contacts

Primary ContactZhanguo Liu, M.D.PhD
zhguoliu@163.com+86-2062782927
Backup ContactXilan Tan, M.D.PhD
147270875@qq.com+86-13751824998

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026